Perpetual Ltd’s Neurocrine Biosciences NBIX Stock Holding History

Perpetual Ltd’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$374K	Sell	2,638 -208	-7%	-$33.4K	0.01%	341
2026 Q2	$480K	Sell	2,846 -513	-15%	-$76.1K	0.01%	331
2026 Q1	$443K	Buy	3,359 +620	+23%	+$82.3K	0.01%	333
2025 Q4	$388K	Buy	+2,739	New	+$397K	0.01%	339
2025 Q3	–	Sell	-2,930	Closed	-$368K	–	435
2025 Q2	$368K	Hold	2,930	–	–	﹤0.01%	357
2025 Q1	$324K	Sell	2,930 -10,171	-78%	-$1.29M	﹤0.01%	367
2024 Q4	$1.79M	Buy	13,101 +541	+4%	+$66.9K	0.02%	201
2024 Q3	$1.45M	Buy	12,560 +6,170	+97%	+$846K	0.02%	224
2024 Q2	$880K	Sell	6,390 -410	-6%	-$56.2K	0.01%	283
2024 Q1	$938K	Buy	6,800 +14	+0.2%	+$1.91K	0.01%	286
2023 Q4	$894K	Buy	+6,786	New	+$781K	0.01%	285
2023 Q3	–	Sell	-2,268	Closed	-$214K	–	486
2023 Q2	$214K	Buy	+2,268	New	+$222K	﹤0.01%	454

Other funds holding NBIX

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return

Ninety One (UK) London, United Kingdom $45.5B AUM 15.2% 1-Year Est. Return

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Seizert Capital Partners Birmingham, Michigan $2.3B AUM 16.06% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Perpetual Ltd's NBIX Position: Q3 2026 in Review

Perpetual Ltd reduced its Neurocrine Biosciences (NBIX) stake by 7.3% in Q3 2026, selling an estimated $33.4K and leaving 2,638 shares worth $374K. The position accounts for 0.01% of the portfolio, ranked #341.

Perpetual Ltd first reported a position in NBIX in Q2 2023 and has held it in 12 quarters since. The position peaked at $1.79M in Q4 2024. 304 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.

Perpetual Ltd held 2,638 shares of Neurocrine Biosciences worth $374K as of Q3 2026.
Perpetual Ltd sold 208 Neurocrine Biosciences shares in Q3 2026, an estimated $33.4K.
Neurocrine Biosciences made up 0.01% of Perpetual Ltd's portfolio in Q3 2026, its #341 holding.
Perpetual Ltd first reported a position in Neurocrine Biosciences in Q2 2023 and has held it in 12 quarters since.
Perpetual Ltd's Neurocrine Biosciences position peaked at $1.79M in Q4 2024.
304 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.

Based on Perpetual Ltd's 13F filing for Q3 2026, filed 13 Oct 2026.